QNT Reclaims the Morgan Stanley Dip as the Buy Stack Overrules the Lone Bear

Reclaiming the Morgan Stanley Dip

Yesterday this was the day's worst-looking quantum name. QNT fell after Morgan Stanley's Joseph Moore initiated coverage at equal-weight with a $78 target — the only cautious note in an otherwise bullish wall of fresh sell-side coverage — and the perp printed an intraday low near $70.77. The recovery since has more than erased that move: at $76.85 the contract is back above where it traded before Moore's note landed, and the 24-hour change now reads +6.97%.

Nothing about the company changed in between. What changed is that the market had a full day to weigh one equal-weight against the stack of Buy and Overweight calls that hit the same week, and it decided the lone bear was outvoted. That is the whole story of the bounce — not a new catalyst, but a repricing of yesterday's overreaction to a single skeptical voice.

What the Bulls Are Underwriting

The bullish coverage arrived in a cluster once QNT's post-IPO quiet period expired on June 29, and the targets are aggressive. Craig-Hallum initiated at Buy with a $100 target on the firm's quantum lead, and it had company in size. Per Barchart's tally, Needham and Bank of America also landed at $100, JPMorgan at $97 Overweight, Evercore ISI at $98 Outperform, while Jefferies, Mizuho, UBS and Cantor Fitzgerald clustered near $90.

The rationale is uniformly about the roadmap, not the current P&L. Needham models commercial revenue inflecting from $31 million in 2025 toward $4.3 billion within five years as the Apollo system scales; BofA points to enterprise customers like Amgen and BMW adopting the Helios platform and a quantum addressable market it sees expanding from roughly $1.1 billion to as much as $80 billion by 2035; JPMorgan leans on a decade-plus of trapped-ion expertise and a commercial pipeline it pegs above $5 billion. Net it out and the consensus now reads Buy with an average target near $93, comfortably above the $76.85 print.

What Still Has to Go Right

None of this changes what the income statement looks like today, which is the exact thing Morgan Stanley refused to pay up for. Quantinuum did about $30.9 million of revenue in 2025, and its most recent quarter actually shrank — revenue fell roughly 73% year over year to about $5.2 million against a net loss near $136.6 million. The offsetting fact is the balance sheet: the company carries roughly $677 million in cash, enough runway to fund years of the burn the bull case requires.

That tension — a roughly $31-million revenue base against a multibillion-dollar valuation — is why this name moves the way it does. With a thin public float since the June 4 Nasdaq debut, where Quantinuum priced an upsized IPO at $60 and raised $1.68 billion, QNT trades almost entirely on sentiment. A single credible voice in either direction can swing it several percent in a day; yesterday Morgan Stanley swung it down, today the consensus swung it back. The roadmap targets won't be falsified for years, so until then the tape will keep moving on whichever side of the sell side speaks loudest.